Equities Analysts Set Expectations for TMO Q2 Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Research analysts at Zacks Research decreased their Q2 2026 earnings estimates for shares of Thermo Fisher Scientific in a research report issued on Wednesday, August 13th. Zacks Research analyst Team now anticipates that the medical research company will earn $6.01 per share for the quarter, down from their previous forecast of $6.94. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.28 per share. Zacks Research also issued estimates for Thermo Fisher Scientific’s FY2026 earnings at $24.21 EPS, Q1 2027 earnings at $6.26 EPS and FY2027 earnings at $27.17 EPS.

A number of other research analysts have also issued reports on TMO. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 10th. UBS Group lifted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. HSBC restated a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Stifel Nicolaus reduced their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research note on Thursday, April 24th. Finally, Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Seven investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $593.00.

Thermo Fisher Scientific Trading Up 1.0%

TMO stock opened at $489.96 on Friday. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company’s 50-day simple moving average is $434.83 and its 200 day simple moving average is $460.05. The company has a market capitalization of $185.01 billion, a PE ratio of 28.34, a price-to-earnings-growth ratio of 2.61 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts’ consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The firm’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $5.37 earnings per share.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently made changes to their positions in the stock. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $25,000. CBIZ Investment Advisory Services LLC boosted its position in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares during the last quarter. Ameriflex Group Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $30,000. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $30,000. Finally, Keystone Global Partners LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $31,000. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 8,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,340,824.30. This trade represents a 6.49% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,400 shares of company stock worth $8,345,792. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.